Our projection for Diagnos in August

In this story, I am going to address all ongoing Diagnos shareholders. I will look into why, despite the ongoing dip, the longer-term fundamental drivers of the firm are still sound. The firm current chance of distress is over 74.0 percent. The company moves slightly opposite to the market. Diagnos secures Sharpe Ratio (or Efficiency) of -0.0085, which denotes the company had -0.0085% of return per unit of standard deviation over the last month. Macroaxis philosophy in predicting the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Diagnos exposes twenty-six different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to confirm Diagnos downside deviation of 9.37, semi deviation of 2.95, and mean deviation of 3.0 to check the risk estimate we provide.
Published over a year ago
View all stories for DIAGNOS | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Raphi Shpitalnik

This firm has a beta of -0.7073. Let's try to break down what Diagnos's beta means in this case. Diagnos returns are very sensitive to returns on the market. As the market goes up or down, Diagnos is expected to follow. The beta indicator helps investors understand whether Diagnos moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Diagnos deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. Diagnos shows negative operation of assets of -96.0 percent, lossing $0.96 for each dollar of assets held by the firm. Unsuccessful asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way asset utilization of Diagnos shows how unproductive it operates for each dollar spent on its assets.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as DIAGNOS. Regardless of method or technology, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for DIAGNOS

Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of DIAGNOS's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as DIAGNOS. Your research has to be compared to or analyzed against DIAGNOS's peers to derive any actionable benefits. When done correctly, DIAGNOS's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in DIAGNOS.

Watch out for price decline

Please consider monitoring DIAGNOS on a daily basis if you are holding a position in it. DIAGNOS is trading at a penny-stock level, and the possibility of delisting is much higher compared to other otcs. However, just because the otc stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as DIAGNOS stock to be traded above the $1 level to remain listed. If DIAGNOS otc stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is DIAGNOS's Liquidity

DIAGNOS financial leverage refers to using borrowed capital as a funding source to finance DIAGNOS ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. DIAGNOS financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to DIAGNOS's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of DIAGNOS's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between DIAGNOS's total debt and its cash.

A Deeper look at DIAGNOS

Diagnos maintains current valuation of 7.76 m. Diagnos reported revenue of 860.59 K. Net Loss for the year was (2.74 M) with loss before overhead, payroll, taxes, and interest of (473.45 K). Diagnos is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about Diagnos implied risk. Diagnos is a potential penny stock. Although Diagnos may be in fact a good instrument to invest, many penny otc stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand upside potential and downside risk of investing in Diagnos. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings,sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that has been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The one and only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Time to bail out on of Diagnos?

Ongoing semi variance is at 8.67. Diagnos is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about Diagnos implied risk. Diagnos is a potential penny stock. Although Diagnos may be in fact a good instrument to invest, many penny otc stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand upside potential and downside risk of investing in Diagnos. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings,sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that has been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The one and only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Bottom Line On Diagnos

While other players in its sector industry are either recoverring, or due for a correction, Diagnos may not be as strong as the other in terms of longer-term growth potentials. In closing, as of 3rd of July 2020, we believe that at this point Diagnos is overvalued with high probability of distress within the next 2 years. Our present buy/sell recommendation on the firm is Strong Sell. With a less-than optimistic outlook for your 30 days horizon, it may be a good time to trade some or all of your Diagnos holdings as it seems the potential growth was already fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Diagnos.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of DIAGNOS. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com